

S&P Capital IQ Initiates Coverage on ANGLE Plc in S&P Capital IQ Factual Stock Reports

PR Newswire
NEW YORK

NEW YORK, March 16, 2015 /[PRNewswire](#)/ -- S&P Capital IQ (MHFI) announced today that it has commenced [Factual Stock Report coverage on ANGLE Plc](#).

ANGLE Plc (OTCQX: ANPCY; LSE AIM: AGL) is a specialist medical diagnostic company with products in cancer diagnostics and fetal health. The company has substantially completed its transition to a specialist medical diagnostics company from a broader venture business building and services based company and GICS codes will be revised in due course. The company's lead product is the patent-protected Parsortix cell separation device, which can capture very rare circulating tumor cells (CTCs) in cancer patient blood, even when there is less than one CTC in one billion healthy cells. The resulting liquid biopsy (simple blood test) enables the investigation of mutations in the patient's cancer for personalized cancer care. ANGLE has launched a product for the research market and has secured CE Mark regulatory approval for the clinical market in Europe. FDA approval is targeted for 2015.

The Parsortix GEN3 Cassette works with a variety of cancers including prostate, breast, ovarian, pancreatic, colorectal, lung and renal. It does not require the use of antibodies and is capable of harvesting circulating tumor cells for molecular analysis.

The Parsortix system has a number of key features. Unlike other systems, the Parsortix system does not rely on the CTCs expressing specific cell surface markers for isolation for antibody binding. This means that all the cancer cells can be captured. In addition, the Parsortix system is applicable for all solid cancers including those with weak or no cell surface markers. The Parsortix system can be used without modification with a wide range of cancers. The company also notes that cells which are captured by the Parsortix system have not been subjected to antibody binding or other chemical reaction as part of the capture process. This offers the potential to capture intact undamaged cells for detailed analysis.

The Parsortix system is biomarker compatible. CTCs captured by the Parsortix system can be harvested for detailed molecular analysis. This liquid biopsy from a simple blood test enables the potential for personalized cancer treatment with patients receiving drugs which directly target their own cancer.

ANGLE says the Parsortix system is easy to use and can be used with whole blood samples, direct from a simple blood test, without any pre-processing of the blood such as red blood cell removal. This makes the process easy and cost effective, the company notes, while ensuring that unnecessary loss of target cells is minimized. ANGLE also notes that the Parsortix system can handle blood volumes of less than 1ml and up to 50ml enabling a wide range of applications.

During FY 14 (April), a specialist, large-scale manufacturer was appointed to manufacture the Parsortix

system with the necessary quality systems and capacity to support the roll out into the research and clinical markets.

ANGLE believes that it made significant progress with commercialization of Parsortix during FY 14, and it is now strongly focused on establishing the use of the system in clinical practice. To achieve this, the top priority is the establishment of collaborations with key opinion leaders at world class research centers. The company says that these key opinion leaders are working to identify applications with medical utility (clear benefit to patients), and to secure clinical data that demonstrates that utility in patient studies.

The company noted that Cancer Research UK Manchester Institute completed a full report confirming key competitive advantages of the Parsortix system. These include applicability to multiple types of cancer cells including mesenchymal cells, applicability to multiple types of cancer, easy harvesting of cells for molecular analysis, and a low level of background white blood cell contamination of harvested cell samples.

In addition, ANGLE has an agreement with the Medical Research Council's Cancer Unit at the University of Cambridge to establish a Cambridge Parsortix Laboratory. The agreement will allow research teams to have improved access to the Parsortix system.

The Parsortix system has also been used by the University of Surrey Oncology Group in a metastatic liver cancer patient study.

On January 23, 2015, the Company announced a collaboration agreement with EKF Diagnostics Holdings plc to investigate the combination of the Parsortix system with EKF's PointMan™DNA enrichment technology as a liquid biopsy.

On January 27, 2015, the company announced that following highly convincing patient data, the Medical University of Vienna reported that the Parsortix system delivers "unprecedented sensitivity and specificity" and will now lead, in collaboration with ANGLE, a clinical study of the use of the Parsortix system as a clinical application in the routine detection and treatment of ovarian cancer patients.

ANGLE's major focus is on the cancer market. However, it believes that there is also a substantial market available in non-invasive fetal diagnostics, harvesting fetal cells from the pregnant mother and analyzing for Down's Syndrome and many other chromosomal and genetic conditions through a simple blood test.

ANGLE Plc is based in Guildford, Surrey, United Kingdom and University City Science Centre, Philadelphia.

[S&P Capital IQ's Factual Stock Report coverage on ANGLE Plc](#) will also be accessible on an ongoing basis to the investment community by scores of buy-side institutions and sell-side firms that utilize S&P Capital IQ research and information platforms daily. Millions of self-directed investors also have access to the report via their e-brokerage accounts. Please visit <http://www.angleplc.com> for additional information.

About S&P Capital IQ's Factual Stock Reports

Currently profiling approximately 400 issuers, S&P Capital IQ (MHFI) Factual Stock Reports increase market awareness of issuers in the investment community with insightful commentary, key statistics, and relevant corporate information. The Reports provide factual research coverage about company fundamentals and business prospects, thereby enabling information on the covered companies to reach a wide spectrum of Buy and Sell-side investors. Updated weekly with the latest pricing, trading volume, and other data, the Reports also capture recent company developments, a financial review, key operating information, industry

and peer comparisons, Street Consensus, performance charts, business summary, fundamental data, and timely news stories. Coverage of these reports is underwritten by the issuer, therefore S&P Capital IQ does not offer investment opinions concerning the advisability of investing in these stocks.

S&P Capital IQ Factual Stock Reports are produced separately from any other analytic activity of S&P Capital IQ or related organizations. S&P Capital IQ does not trade on its own account.

About S&P Capital IQ

S&P Capital IQ, a part of McGraw Hill Financial (NYSE: MHFI), is a leading provider of multi-asset class and real time data, research and analytics to institutional investors, investment and commercial banks, investment advisors and wealth managers, corporations and universities around the world. S&P Capital IQ provides a broad suite of capabilities designed to help track performance, generate alpha, and identify new trading and investment ideas, and perform risk analysis and mitigation strategies. Through leading desktop solutions such as the S&P Capital IQ, Global Credit Portal and MarketScope Advisor desktops; enterprise solutions such as S&P Capital IQ Valuations; and research offerings, including Leveraged Commentary & Data, Global Markets Intelligence, and company and funds research, S&P Capital IQ sharpens financial intelligence into the wisdom today's investors need. For more information, visit www.spcapitaliq.com.

In the United States, research reports are prepared by Standard & Poor's Investment Advisory Services LLC, a part of S&P Capital IQ and a registered investment adviser with the U.S. Securities and Exchange Commission. S&P Capital IQ provides a broad suite of capabilities designed to help track performance, generate alpha, and identify new trading and investment ideas, and perform risk analysis and mitigation strategies.

SOURCE S&P Capital IQ

<http://press.spglobal.com/2015-03-16-S-P-Capital-IQ-Initiates-Coverage-on-ANGLE-Plc-in-S-P-Capital-IQ-Factual-Stock-Reports>